Here is the antigen used for this clinician-sponsored trial (open label, primary completion date 7/20)...........
clinicaltrials.gov
Clin Cancer Res. 2015 Sep 1;21(17):3879-87. doi: 10.1158/1078-0432.CCR-15-0233. Epub 2015 May 12.
Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival.
Reed CM1, Cresce ND1, Mauldin IS1, Slingluff CL Jr1, Olson WC2.
1
Department of Surgery, University of Virginia, Charlottesville, Virginia.
2
Department of Surgery, University of Virginia, Charlottesville, Virginia. wco3j@virginia.edu.
PURPOSE:
A melanoma vaccine incorporating six peptides designed to induce helper T-cell responses to melanoma antigens has induced Th1-dominant CD4(+) T-cell responses in most patients, and induced durable clinical responses or stable disease in 24% of evaluable patients. The present study tested whether this vaccine also induced antibody (Ab) responses to each peptide, and whether Ab responses were associated with T-cell responses and with clinical outcome.
EXPERIMENTAL DESIGN:
Serum samples were studied from 35 patients with stage III-IV melanomas vaccinated with 6 melanoma helper peptides (6MHP). IgG Ab responses were measured by ELISA. Associations with immune response and overall survival were assessed by log-rank test and ?(2) analysis of Kaplan-Meier data.
RESULTS:
Ab responses to 6MHP were detected by week 7 in 77% of patients, and increased to peak 6 weeks after the last vaccine and persisted to 6 months. Ab responses were induced most frequently to longer peptides. Of those with T-cell responses, 82% had early Ab responses. Survival was improved for patients with early Ab response (P = 0.0011) or with early T-cell response (P < 0.006), and was best for those with both Ab and T-cell responses (P = 0.0002).
CONCLUSIONS:
Vaccination with helper peptides induced both Ab responses and T-cell responses, associated with favorable clinical outcome. Such immune responses may predict favorable clinical outcome to guide combination immunotherapy. Further studies are warranted to understand mechanisms of interaction of these Abs, T-cell responses, and tumor control.
This related study, also at Univ. Virginia, was halted for lack of accrual.....
clinicaltrials.gov
Not much recent work with 6MHP. We should assign $0 to this trial. But I'm pleased that the investigators are pursuing this approach |
